HeartBeam Narrows Loss, Advances Commercial Launch of Cardiac Monitoring Platform
HeartBeam reported a narrower net loss in Q1 2026 as it launched commercial partnerships in key U.S. markets for its FDA-cleared 3D ECG platform, which could transform cardiac care outside medical facilities.
